Efficacy and Safety of Olaparib in Participants With Previously Treated, Homologous Recombination Repair Mutation or Homologous Recombination Deficiency Positive Advanced Cancer
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to